Unicycive Therapeutics Stock
Unicycive Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shalabh K. Gupta
- Employees
- 21
- Market cap
- $92 M
- IPO
- 12/07/2021
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury.…
Unicycive Therapeutics stock: price history
1D
-6.4%
1W
-18.2%
1M
-29.7%
6M
-52.1%
YTD
-41.8%
1Y
-31.8%
2Y
-17.6%
5Y
-87.6%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~13% stronger price swings than usual
Ask the agents about Unicycive Therapeutics
Analyst assessment of Unicycive Therapeutics
PRICE TARGET LOW
US$22.00
CONSENSUS
US$22.00
MEDIAN
US$22.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 29/09/2026
Unicycive Therapeutics stock metrics
P/E
-2.01
P/B
1.7
EV/EBITDA
-1.41
RETURN ON EQUITY
-3.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.4%
FLOAT SHARES
26,675,600
AVG. DAILY VOLUME (30D)
954,631
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Unicycive Therapeutics stock
What does Unicycive Therapeutics do?
Unicycive Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shalabh K. Gupta, the company employs around 21 people.
The IPO was on 12/07/2021; the stock trades on NASDAQ under the ticker UNCY.
What do analysts say about Unicycive Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$22.00, ranging from US$22.00 to US$22.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does Unicycive Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 13% stronger than usual.
Does Unicycive Therapeutics pay a dividend?
No, Unicycive Therapeutics currently does not pay a dividend.
Which stocks are comparable to Unicycive Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Unicycive Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Unicycive Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.